EXAS Stock Recent News

Exact Sciences stock bounded higher Thursday after beating second-quarter expectations, signaling a return to growth for Cologuard.

Exact Sciences (EXAS) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.37. This compares to loss of $0.45 per share a year ago.

Exact Sciences Corporation (NASDAQ:EXAS ) Q2 2024 Earnings Conference Call July 31, 2024 5:00 PM ET Company Participants Erik Holznecht - Manager, Investor Relations Kevin Conroy - Chairman and Chief Executive Officer Aaron Bloomer - Chief Financial Officer Conference Call Participants Patrick Donnelly - Citi Tycho Peterson - Jefferies Andrew Brackman - William Blair Catherine Schulte - Baird Matt Sykes - Goldman Sachs Dan Arias - Stifel Doug Schenkel - Wolfe Research Vijay Kumar - Evercore ISI Dan Brennan - TD Cowen Jack Meehan - Nephron Research Michael Ryskin - Bank of America Puneet Souda - Leerink Partners Subbu Nambi - Guggenheim Operator Thank you for standing by. At this time, I would like to welcome everyone to today's Exact Sciences Second Quarter 2024 Earnings Call.

24/7 Wall Street Insights Early cancer detection is the first line of defense in preventing the disease's progression and reducing fatalities.

Exact Sciences (EXAS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

In June, we profiled biotech exchange-traded fund (ETF) SPDR S&P Biotech ETF (XBI) amid a historically bullish month.

Exact Sciences is facing a barrage of headwinds. The company's financial results haven't been good of late.

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its second quarter 2024 financial results after the close of the U.S. financial markets on July 31, 2024. Following the release, company management will host a webcast and conference call at 5 p.m. ET to discuss financial results and business progress. Second quarter 2024 webcast & conference call details Date: We.

The personalized medicine market is experiencing significant growth, driven by advancements in genomic technologies and a shift towards more individualized healthcare. In 2024, the market is expected to continue expanding, with projections indicating it could reach approximately $390.65 billion, growing at a compound annual growth rate (CAGR) of around 8.20% from 2024 to 2030.

We are almost halfway through 2024, and the stock market is putting on a masterclass performance. The S&P 500 is up 12% year-to-date after rising 23% last year.